Humira to be launched in Korea

Published: 2006-12-19 06:56:00

Updated: 2006-12-19 06:56:00

Abbott Korea said on December 18 that it will launch HUMIRA (adalimumab), a human-derived antibody that binds to human tumor necrosis factor alpha (TNF alpha), from next year, as its efficacy and safety were assessed in the local double-blind, placebo-controlled studies in adult patients.

HUMI...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK